Aclaris Therapeutics, Inc. (ACRS): Price and Financial Metrics

Aclaris Therapeutics, Inc. (ACRS): $1.23

0.01 (+0.41%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

D

ACRS Price/Volume Stats

Current price $1.23 52-week high $11.12
Prev. close $1.22 52-week low $0.59
Day low $1.22 Volume 367,531
Day high $1.25 Avg. volume 1,507,462
50-day MA $1.22 Dividend yield N/A
200-day MA $3.91 Market Cap 86.88M

ACRS Stock Price Chart Interactive Chart >


Aclaris Therapeutics, Inc. (ACRS) Company Bio


Aclaris Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company focused on identifying, developing, and commercializing novel drugs to address unmet needs in dermatology. The company was founded in 2012 and is based in Malvern, Pennsylvania.


ACRS Latest News Stream


Event/Time News Detail
Loading, please wait...

ACRS Latest Social Stream


Loading social stream, please wait...

View Full ACRS Social Stream

Latest ACRS News From Around the Web

Below are the latest news stories about ACLARIS THERAPEUTICS INC that investors may wish to consider to help them evaluate ACRS as an investment opportunity.

Aclaris Therapeutics Provides Corporate Update

- ATI-1777 Phase 2a Trial Results Published in JID Innovations -- ATI-1777 Phase 2b Trial Topline Data Anticipated in January 2024 -- Aclaris Announces Reduction in Workforce - WAYNE, Pa., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drugs for immuno-inflammatory diseases, today announced several corporate updates. First, Aclaris announced the publication of the Phase 2a trial results of ATI-17

Yahoo | December 19, 2023

Aclaris Therapeutics Announces Patent License Agreement with Sun Pharma for Alopecia

WAYNE, Pa., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drugs for immuno-inflammatory diseases, today announced an exclusive patent license agreement with Sun Pharmaceutical Industries, Inc. (Sun Pharma). Under the license agreement, Aclaris granted Sun Pharma exclusive rights under certain patents for the use of deuruxolitinib, Sun Pharma’s JAK inhibitor, or other isotopic forms of ruxolitini

Yahoo | December 5, 2023

Aclaris (ACRS) Loses -83.17% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Aclaris (ACRS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Yahoo | December 4, 2023

Down -84.82% in 4 Weeks, Here's Why You Should You Buy the Dip in Aclaris (ACRS)

Aclaris (ACRS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Yahoo | November 16, 2023

Aclaris (ACRS) Lead Drug Fails Rheumatoid Arthritis Study

Aclaris (ACRS) decides to stop the development of its lead drug after top-line data from a mid-stage study did not achieve any study goals. Shares plunge 86% following the news.

Yahoo | November 14, 2023

Read More 'ACRS' Stories Here

ACRS Price Returns

1-mo 6.96%
3-mo -2.38%
6-mo -73.14%
1-year -86.45%
3-year -95.39%
5-year -81.99%
YTD 17.14%
2023 -93.33%
2022 8.32%
2021 124.73%
2020 242.33%
2019 -74.42%

Continue Researching ACRS

Want to see what other sources are saying about Aclaris Therapeutics Inc's financials and stock price? Try the links below:

Aclaris Therapeutics Inc (ACRS) Stock Price | Nasdaq
Aclaris Therapeutics Inc (ACRS) Stock Quote, History and News - Yahoo Finance
Aclaris Therapeutics Inc (ACRS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!